On Monday, Following Stocks were among the “Top 100 Best Stocks” of U.S. Stock Market: RADA Electronic Industries Ltd. (NASDAQ:RADA), Incyte Corporation (NASDAQ:INCY), Peabody Energy Corp. (NYSE:BTU), Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
RADA Electronic Industries Ltd. (NASDAQ:RADA), with shares skyrocketed 71.60%, closed at $2.90.
Incyte Corporation (NASDAQ:INCY), with shares lost -2.26%, settled at $93.39.
Peabody Energy Corp. (NYSE:BTU), with shares climbed 3.91%, and closed at $6.38.
Nymox Pharmaceutical Corporation (NASDAQ:NYMX), surged 27.29%, and closed at $0.70.
Latest NEWS regarding these Stocks are depicted underneath:
RADA Electronic Industries Ltd. (NASDAQ:RADA)
RADA Electronic Industries Ltd. (RADA), declared the selection by Lockheed Martin Space Systems Corporation of its Multi-Mission Hemispheric Radar (MHR) to support internally funded high energy laser weapon system prototype testing. The radar will be used by Lockheed Martin in combination with other sensors.
The MHR — an S-Band, Software-Defined, Pulse-Doppler, Active Electronically Scanned Array radar — has sophisticated beam forming capabilities and advanced signal processing, provides multiple missions on each radar platform, and offers unprecedented performance-to-price ratio. It is compact and mobile, delivering ideal organic, tactical surveillance solutions for force and border protection applications such as counter rockets and mortars, counter unmanned aerial systems, ground moving target indicator, air surveillance, and more.
According to Zvi Alon, RADA’s CEO, “We are very happy with Lockheed Martin’s selection of our unique MHR, which is particularly suited for use with systems that counter rockets and mortars.”
RADA Electronic Industries Ltd., a defense electronics contractor, is engaged in the development, manufacture, and sale of defense electronics to various air forces and companies worldwide.
Incyte Corporation (NASDAQ:INCY)
Incyte Corporation (INCY), declared that Novartis received approval from the European Commission for Jakavi® (ruxolitinib) for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea. Jakavi is the first targeted treatment approved by the European Commission for these patients.
Under the Incyte-Novartis Partnership and License Contract signed in 2009, Novartis received exclusive development and commercialization rights to ruxolitinib outside of the United States for all hematologic and oncologic indications, and sells ruxolitinib under the name Jakavi. Ruxolitinib is marketed by Incyte in the United States as Jakafi® (ruxolitinib). Jakafi® is approved by the U.S. Food and Drug Administration for treatment of people with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi is also indicated for treatment of people with intermediate or high-risk myelofibrosis (MF), counting primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF.
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical corporation focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology.
Peabody Energy Corp. (NYSE:BTU)
Formerly on March 16, Peabody Energy Corp. (BTU), declared that the early tender period for the formerly declared tender offer to purchase for cash any and all of the $650 million aggregate principal amount outstanding of its 7 3/8% Senior Notes due 2016 expired at 5:00 p.m., New York City time, on March 13, 2015. Holders of notes that were validly tendered and not validly withdrawn on or preceding to 5:00 p.m. on March 13, 2015, received the total consideration of $1,102.71 per $1,000 principal amount, which comprises of a $30.00 early tender premium for each $1,000 principal amount of notes plus the tender offer consideration of $1,072.71 per $1,000 principal amount. Holders whose notes were accepted for purchase also received accrued and unpaid interest on their purchased notes from the applicable last interest payment date to, but not counting, March 16, 2015.
At the deadline of 5:00 p.m., New York City time, March 13, 2015, $565,651,000 principal amount of all outstanding notes were tendered and not validly withdrawn, representing about 87% of all outstanding notes.
The offer is planned to expire at 11:59 p.m., New York City time, on March 27, 2015, unless extended. Holders who have not already tendered their notes may do so at any time on or preceding to 11:59 p.m., New York City time, on March 27, 2015. Such holders will only be eligible to receive the tender offer consideration. The offer comprises an early settlement option which the Corporation elected to use and the initial settlement date was recently, March 16, 2015. Peabody issued a notice of redemption with respect to any notes not tendered in the tender offer and anticipates to redeem any such notes on April 15, 2015. Peabody reserves the right to terminate, withdraw or amend the offer at any time, as described in the offer to purchase.
Peabody Energy is the world’s largest private-sector coal corporation and a global leader in sustainable mining, energy access and clean coal solutions. The corporation serves metallurgical and thermal coal customers in more than 25 countries on six continents.
Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Nymox Pharmaceutical Corporation (NYMX), declared recent private placements of 883,058 shares, with total proceeds of US$400,000. An additional 441,529 warrants exercisable at $2.00 were comprised of in the private placements.
Nymox Pharmaceutical Corporation, a biopharmaceutical corporation, is engaged in the research and development of products for the aging population. It provides NicAlert and TobacAlert products that use urine or saliva to detect use of and exposure to tobacco products, in addition to AlzheimAlert, a proprietary urine assay that aid physicians in the diagnosis of Alzheimer’s disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
